Cellect Biotechnology: Gains on new patent allowance in Canada

Quoin Pharmaceuticals

27/04/2020 16:40

** U.S. shares of Israel-based stem cell therapy developer
 APOP.O  rise ~4% to $2.50
    ** Canadian Intellectual Property Office grants APOP patent
for a device and kit adapted to select cells resistant to
receptor-mediated apoptosis, which is process of programmed cell
death  urn:newsml:reuters.com:*:nPn2lq4ZSa
    ** Device can help selection of stem cells from any given
tissue, and aims to improve variety of stem cell-based therapies
- APOP
    ** Including session's gain, shares have risen ~13% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))